In conclusion, using the novel AdRGD-PG vectors, the combined p19Arf and IFNβ gene therapy approach induces high levels of cell death, summons the immune system to the battle and, as a result, is predicted to have a wide-spread impact on tumor inhibition. The gene discussed is IFNB1; the disease is neoplasm.